Effect of adjuvant composition on immune response to a multiple antigen peptide (MAP) containing a protective epitope from Neisseria meningitidis class 1 porin

Vaccine

Volumn 18, Issue 1-2, 1999, Pages 131-139

  Christodoulides, Myron ^a   Rattue, Elizabeth ^a   Heckels, John E ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Adjuvant; Meningococci; Peptide vaccine

Indexed keywords

ANTIGEN; EPITOPE; FREUND ADJUVANT; OUTER MEMBRANE PROTEIN; PORIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; MENINGOCOCCOSIS; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURFACE PLASMON RESONANCE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; EPITOPES; IMMUNE SERA; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS; PORINS;

EID: 0033588520     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00190-5     Document Type: Article

References (37)

1. Bjune G., Hoiby E.A., Gronnesby J.K., Arnesen O., Holstfredriksen J., Halstensen A., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 338:1991;1093-1096.
2. Demoraes J.C., Perkins B.A., Camargo M.C.C., Hidalgo N.T.R., Barbosa H.A., Sacchi C.T., et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 340:1992;1074-1078.
3. Boslego J., Garcia J., Cruz C., Zollinger W., Brandt B., Ruiz S., et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15-P1.3) outer-membrane protein vaccine in Iquique, Chile. Vaccine. 13:1995;821-829.
4. Perkins B.A., Jonsdottir K., Briem H., Griffiths E., Plikaytis B.D., Hoiby E.A., et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 177:1998;683-691.
5. Rosenqvist E., Hoiby E.A., Wedege E., Bryn K., Kolberg J., Klem A., et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:1995;4642-4652.
6. Milagres L.G., Ramos S.R., Sacchi C.T., Melles C.E.A., Vieira V.S.D., Sato H., et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 62:1994;4419-4424.
7. Wedege E., Froholm L.O. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect. Immun. 51:1986;571-578.
8. van der Voort E.R., van der Ley P., van der Biezen J., George S., Tunnela O., van Dijken H., et al. Specificity of human bactericidal antibodies against PorA P1.7, 16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect. Immun. 64:1996;2745-2751.
9. Jones G.R., Christodoulides M., Brooks J.L., Miller A.R.O., Cartwright K.A.V., Heckels J.E. Dynamics of carriage of Neisseria meningitidis in a group of military recruits: subtype stability and specificity of the immune response following colonisation. J. Infect. Dis. 178:1998;451-459.
10. Idanpaan-Heikkila I., Hoiby E.A., Chattopadhyay P., Airaksinen U., Michaelsen T.M., Wedege E. Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease. J. Med. Microbiol. 43:1995;335-343.
11. Barlow A.K., Heckels J.E., Clarke I.N. The class 1 outer membrane protein of Neisseria meningitidis: gene sequence and structural and immunological similarities to gonococcal porins. Mol. Microbiol. 3:1989;131-139.
12. van der Ley P., Heckels J.E., Virji M., Hoogerhout P., Poolman J.T. Topology of outer membrane porins in pathogenic Neisseria spp. Infect. Immun. 59:1991;2963-2971.
13. McGuinness B.T., Lambden P R., Heckels J.E. Class 1 outer membrane protein of Neisseria meningitidis: epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology. Mol. Microbiol. 7:1993;505-514.
14. Saukkonen K., Abdillahi H., Poolman J.T., Leinonen M. Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development. Microb. Path. 3:1987;261-267.
15. Claassen I., Meylis J., van der Ley P., Peeters C., Brons H., Robert J., et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine. 14:1996;1001-1008.
16. Peeters C.C.A.M., Rumke H.C., Sundermann L.C., van der voort E.M.R., Meulenbelt J., Schuller M., et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine. 14:1996;1009-1015.
17. Christodoulides M., McGuinness B.T., Heckels J.E. Immunisation with synthetic peptides containing epitopes of the class 1 outer membrane protein of Neisseria meningitidis: production of bactericidal antibodies on immunisation with a cyclic peptide. J. Gen. Microbiol. 139:1993;1729-1738.
18. Hoogerhout P., Donders E.M.L.M., Van den Brink J.A.M.V.G., Kuipers B., Brugghe H.F., Van Unen L.M.A., et al. Conjugates of synthetic cyclic peptides elicit bactericidal antibodies against a conformational epitope on a class 1 outer membrane protein of Neisseria meningitidis. Infect. Immun. 63:1995;3473-3478.
19. Christodoulides M., Heckels J.E. Immunisation with multiple antigen peptides containing B- and T- cell epitopes: production of bactericidal antibodies towards Neisseria meningitidis. Microbiology. 140:1994;2951-2960.
20. Tinsley C.R., Heckels J.E. Variation in the expression of pili and outer membrane protein by Neisseria meningitidis during the course of meningococcal infection. J. Gen. Microbiol. 132:1986;2483-2490.
21. Relyveld E., Bengounia A., Huet M., Kreeftenberg J.G. Antibody response of pregnant women to two different adsorbed tetanus toxoids. Vaccine. 9:1991;369-372.
22. Byars N.E., Allison A.C. Adjuvant formulation for use in vaccines to elicit both cell- mediated and humoral immunity. Vaccine. 5:1987;223-228.
23. Geerligs H.J., Weijer W.J., Welling G.W., Wellingwester S. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D. J. Immunol. Meth. 124:1989;95-102.
24. Christodoulides M., Brooks J.L., Rattue E., Heckels J.E. Immunisation with recombinant class 1 outer membrane protein from Neisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci. Microbiology. 144:1998;3027-3037.
25. Jonsson U., Fagerstam L., Ivarsson B., Johnsson B., Karlsson R., Lundh K., et al. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques. 11:1991;620-627.
26. Van Cott T.C., Bethke F.R., Polonis V.R., Gorny M.K., Zollapazner S., Redfield R.R., et al. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J. Immunol. 153:1994;449-459.
27. Takayama K., Olsen M., Datta P., Hunter R L. Adjuvant activity of non-ionic block copolymers. v. Modulation of antibody isotype by lipopolysaccharides, lipid-A and precursors. Vaccine. 9:1991;257-265.
28. Hunter R.L., Olsen M.R., Bennett B. Copolymer adjuvants and Titermax. Stewart-Tull D.E.S. The theory and practical application of adjuvants. 1995;51-94 Wiley, Chichester.
29. Baker P.J., Fauntleroy M.B., Prescott B. Examination of the differential characteristics of amplifier and contra-suppressor T-cells. Immunobiology. 177:1988;438-448.
30. Takada H., Kotani S. Muramyl dipeptide and derivatives. Stewart-Tull D.E.S. The theory and practical application of adjuvants. 1995;171-202 Wiley, Chichester.
31. 5, I: Effects of carrier, copolymer adjuvants and lipopolysaccharide on isotype selection. J. Immunol. 146:1991;3583-3590.
32. Kenney J.S., Hughes B.W., Masada M P., Allison A.C. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J. Immunol. Meth. 121:1989;157-166.
33. Karlsson R., Michaelsson A., Mattsson L. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J. Immunol. Meth. 145:1991;229-240.
34. Kaji M., Kaji Y., Honda T., Oka T., Sakoh M., Ohkuma K., et al. Phase I clinical tests of influenza MDP-virosome vaccine (KD-5382). Vaccine. 10:1992;663-667.
35. Hoffman S.L., Edelman R., Bryan J.P., Schneider I., Davis J., Sedegah M., et al. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell-wall skeleton of mycobacteria, and squalane as adjuvant. Am. J. Tropical Med. Hyg. 51:1994;603-612.
36. Quan W.D.Y., Dean G.E., Spears L., Spears C.P., Groshen S., Merritt J.A., et al. Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-M. J. Clin. Oncol. 15:1997;2103-2110.
37. Thoelen S., VanDamme P., Mathei C., LerouxRoels G., Desombere I., Safary A., et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine. 16:1998;708-714.